The growing foothold of personalized medicine and an increasing number of orphan drug formulations are opening new avenues for biotechnology applications and are driving the influx of emerging and innovative biotechnology companies, further boosting market revenue.
Given the growing demand for innovative medical solutions, higher R&D initiatives, and rising investments in biopharma, the biotech industry is thriving. Given the backdrop, it could be wise to invest in these three fundamentally strong biotech stocks.
This post originally appeared at StockNews.com.